You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Summary of health care system expenditure, by country 2013, £ million and % of total

From: The economic impact of sight loss and blindness in the UK adult population

  England Wales Scotland Northern Ireland UK
Hospital recurrent expenditure 588.9, 23.9% 44.7, 29.6% 85.9, 29.4% 15.3, 19.1% 734.9, 24.6%
Non-admitted expenditure 673.8, 27.3% 33.7, 22.3% 47.3, 16.2% 16.3, 20.3% 771.1, 25.8%
 Prescribing expenditure 137.9, 5.6% 9.0, 6.0% 11.8, 4.0% 3.9, 4.9% 162.6, 5.4%
 Ranibizumab (Lucentis)a 184.0, 7.5% 11.6, 7.7% 17.5, 6.0% 5.2, 6.5% 218.3, 7.3%
General ophthalmic services (GOS) 481.1, 19.5% 32.3, 21.4% 80.9, 27.7% 20.2, 25.2% 614.6, 20.6%
Expenditure associated with injurious falls 19.9, 0.8% 1.0, 0.7% 2.0, 0.7% 0.6, 0.7% 23.4, 0.8%
  (16.2, 0.7% - 23.7, 1.0%) (0.8, 0.5% - 1.2, 0.8%) (1.6, 0.5% - 2.4, 0.8%) (0.5, 0.6% - 0.7, 0.9%) (19.1, 0.6% - 28.0, 0.9%)
Research and development 14.1, 0.6% 0.5, 0.3% 2.1, 0.7% 0.3, 0.4% 17.0, 0.6%
Residential care and community care services 220.8, 9.0% 13.2, 8.7% 31.7, 10.9% 11.0, 13.7% 276.8, 9.3%
Capital and administration 145.7, 5.9% 5.1, 3.4% 12.8, 4.4% 7.1, 8.9% 170.7, 5.7%
Total 2466.1 151.1 292.1 80.1 2989.3
  (2462.4–2469.9) (150.9–151.3) (291.7–292.4) (80.0–80.2) (2985.0–2993.9)
  1. aRanibizumab (Lucentis) sales data for the UK has been split based on the estimates of prevalence for AMD